Vigil Neuroscience, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used by operating activities:
Stock-based compensation expense
Non-cash operating lease expense
Depreciation and amortization
Amortization of premium/discount on marketable securities
Realized gain on investments
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Contract liability
Accrued expenses and other current liabilities
Operating lease liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of marketable securities
Proceeds from sales and maturities of marketable securities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs
Proceeds from issuance of pre-funded warrants from PIPE, net of offering costs
Payments of finance lease obligations
Proceeds from stock option exercised
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series A & Series B Preferred Stock to common stock, net of Issuance costs
Deferred offering costs paid in the prior year
Right-of-use assets obtained in exchange for operating lease liabilities
Prepaid rent reclassified to right-of-use assets
Purchases of property and equipment included in accounts payable and accrued expenses

Comments